NASDAQ:AYTU Aytu BioPharma Q1 2027 Earnings Date & Estimates $1.96 -0.05 (-2.49%) Closing price 10/21/2026 04:00 PM EasternExtended Trading$1.98 +0.02 (+1.02%) As of 10/21/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aytu BioPharma is estimated to report Q1 2027 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ1 2027Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Aytu BioPharma in Q1 2027Aytu BioPharma is expected to post earnings of -$0.2567 per share on revenue of $13.27 million. In the same quarter a year earlier Aytu BioPharma reported -$0.08 per share on revenue of $13.89 million. Aytu BioPharma last reported on May 13, 2026, posting -$0.53 per share and missing the -$0.4433 consensus estimate. Aytu BioPharma has beaten the consensus EPS estimate in 2 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.2567Expected Revenue$13.27 millionPrior-Year EPS-$0.08Prior-Year Revenue$13.89 millionExpected Revenue Growth-4.4%Recent Track RecordLast ReportedQ3 2026Last Quarter EPS-$0.53 (Missed by -$0.0867)Last Quarter Revenue$12.41 millionEPS Beat Rate2 of last 7 quartersPrepare for the Q1 2027 CallEarnings HistoryCompany ProfileQ3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Aytu BioPharma Q1 2027 Earnings FAQ When does Aytu BioPharma report Q1 2027 earnings? Aytu BioPharma (NASDAQ:AYTU) is estimated to report Q1 2027 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Aytu BioPharma's Q1 2027 earnings call? Aytu BioPharma's Q1 2027 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Aytu BioPharma? Analysts expect Aytu BioPharma to post earnings of -$0.2567 per share for Q1 2027. How much revenue is Aytu BioPharma expected to report? The consensus revenue estimate for Aytu BioPharma is $13.27 million for Q1 2027. Aytu BioPharma Earnings HeadlinesAytu BioPharma no Lytham Partners Fall 2026: EXX impulsiona transiçãoSeptember 29, 2026 | br.investing.comAytu BioPharma op Lytham Partners najaar 2026: EXXUA drijft verschuivingSeptember 29, 2026 | nl.investing.com80 Days Until the Pentagon Restricts Chinese Rare EarthsChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports to the U.S. With a January 1, 2027 deadline approaching, the Pentagon selected four companies to build critical mineral processing facilities on U.S. military bases. Only one was chosen for heavy rare earths - a Nasdaq-listed firm with an Ohio metallurgy facility under Pentagon contracts and rights to 80% of output from a major Canadian processing plant.October 22 at 1:00 AM | The Tomorrow Investor (Ad)Aytu BioPharma en Lytham Partners Otoño 2026: EXXUA impulsa cambioSeptember 29, 2026 | mx.investing.comAytu BioPharma, Inc. Q4 2026 Earnings Call SummarySeptember 24, 2026 | finance.yahoo.comAytu BioPharma第四财季营收超预期31%，EXXUA销售强劲推动增长September 23, 2026 | cn.investing.comSee More Aytu BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aytu BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aytu BioPharma and other key companies, straight to your email. Email Address About Aytu BioPharmaAytu BioPharma (NASDAQ:AYTU), Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription medicines for pediatric and primary-care markets. The company’s portfolio includes treatments for attention-deficit/hyperactivity disorder (ADHD), along with products addressing allergies, respiratory conditions, and other common health needs. Aytu’s ADHD portfolio has included orally disintegrating and liquid formulations designed for children and adolescents, such as Adzenys XR-ODT, Cotempla XR-ODT, and Dyanavel XR. The company has also marketed pediatric healthcare products, including prescription and over-the-counter medicines intended to improve convenience, dosing flexibility, and adherence for patients and caregivers. Founded in 2015 and headquartered in Englewood, Colorado, Aytu expanded its commercial portfolio through product acquisitions, including the acquisition of Neos Therapeutics in 2020. The company primarily serves the U.S. healthcare market through its commercial operations and relationships with healthcare providers, pharmacies, and distributors.View Aytu BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX Earnings Launch: High Margins Fund AI AmbitionsGM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?Synchrony Aces The Quarter As Credit Fears FadeHigher Rates Are Sending Investors to These 3 Dividend KingsServiceNow Orchestrates AI's Next Act—Can Earnings Deliver?Are RTX Corporation and Northrop Grumman Ready to Break Out?Swiping to Record Highs: Why Visa Remains a Fortress Upcoming Earnings ENI (10/23/2026)SLB (10/23/2026)American Express (10/23/2026)Infosys (10/23/2026)Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
